During this segment, the panelists share their final insights about the future of immunotherapy.
Jeffrey Weber, MD, PhD, believes that treating patients with immunotherapy will benefit all parties involved in healthcare and does not fear the shift toward “Obamacare.” Dr Weber explains that even as treatment decisions become more data driven, he does not believe that much will change in the way that great physicians consider and treat their patients.
Daniel J. George, MD, is equally excited for the future of immunotherapy, although he is concerned that there is currently an educational lag when considering the different factors associated with immunotherapy. However, he does believe that as immunotherapy becomes a more common treatment modality for fields other than oncology, this barrier will be overcome.
Michael Kolodziej, MD, concludes the discussion by explaining that immunotherapy is in its “golden age.” Furthermore, Dr Kolodziej believes that healthcare reform offers the oncology field, pharmaceutical industry, and the entire healthcare enterprise the opportunity to redefine their roles in positive ways.
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.
Read More